Eli Lilly CEO Dave Ricks has criticized the White House's push to codify "most favored nation" drug pricing deals, stating that it would be bad policy. The deals were signed by more than a dozen drugmakers who agreed to charge similar prices for prescription drugs in the U.S. as other wealthy nations. The White House has been pushing for Congress to codenise elements of the deals, but has been unsuccessful in securing them.